Physician profile
Brandon Paritz
NPI 1568724052
$1,096.07
in general payments reported to CMS, 2019-2025
21 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $316 · 2023: $237 · 2024: $256 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $210.60 | 2022-2025 | Evenity, Prolia |
| Lilly USA, LLC | $171.44 | 2021-2024 | Mounjaro |
| Abbvie INC. | $146.44 | 2021-2025 | |
| Mylan Specialty L.P. | $106.01 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.06 | 2021-2023 | Tradjenta |
| Sanofi-Aventis U.S. LLC | $55.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $53.89 | 2023-2025 | Gvoke Hypopen |
| Viatris Specialty LLC | $40.94 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $37.48 | 2022 | |
| Idorsia Pharmaceuticals US INC | $27.96 | 2022 | |
| Dexcom, INC. | $27.54 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $27.00 | 2023 | |
| Sunovion Pharmaceuticals INC. | $20.99 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.73 | 2024 | Qelbree |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.84 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $15.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.02 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.65 | 2021 | |
| Upsher-Smith Laboratories LLC | $13.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.61 | 2021 | |
| Bioventus LLC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Paritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.